{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:25:38Z","timestamp":1762867538293,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jfo.2017.09.029","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T21:09:22Z","timestamp":1535576962000},"page":"e381-e382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chalazia associated with bortezomib therapy"],"prefix":"10.1016","volume":"41","author":[{"given":"N.","family":"Laaribi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Abdellaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Abaloun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fiqhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rabii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Haidouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Mouzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"El Asri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Reda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oubaaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2017.09.029_bib0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaophthalmol.2015.3963","article-title":"Association between bortezomib therapy and eyelid chalazia","volume":"134","author":"Fraunfelder","year":"2016","journal-title":"JAMA Opthalmol"},{"key":"10.1016\/j.jfo.2017.09.029_bib0055","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.4081\/hr.2015.5729","article-title":"Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy","volume":"7","author":"Yun","year":"2015","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jfo.2017.09.029_bib0060","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2017.09.029_bib0065","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMicm041166","article-title":"Images in clinical medicine. Bortezomib-induced skin lesions","volume":"352","author":"Agterof","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jfo.2017.09.029_bib0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2437.x","article-title":"Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient: association with pro-inflammatory cytokines","volume":"76","author":"Min","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jfo.2017.09.029_bib0075","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2014.04.021","article-title":"Chalazia associated with bortezomib therapy for multiple myeloma","volume":"121","author":"Min","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2017.09.029_bib0080","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clml.2016.04.013","article-title":"Treatment with doxycycline for severe bortezomib associated blepharitis","volume":"16","author":"Veys","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jfo.2017.09.029_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2437.x","article-title":"Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient: association with pro-inflammatory cytokines","volume":"76","author":"Min","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jfo.2017.09.029_bib0090","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer, part II: targeted therapy","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551218302791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551218302791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:09:00Z","timestamp":1759259340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551218302791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0181551218302791"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2017.09.029","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chalazia associated with bortezomib therapy","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2017.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}